GUT: IBD中的抗TNF治疗是通过巨噬细胞IL-10信号发挥其治疗作用的

2019-10-05 不详 MedSci原创

巨噬细胞白介素(IL)-10信号在预防IBD发生中起着关键作用。先前已经发现抗肿瘤坏死因子(TNF)单克隆抗体可以通过Fcγ受体(FcγR)信号起作用,并促进促炎性肠巨噬细胞重新极化为CD206 +调节表型。但是尚未检测IL-10在抗TNF诱导的巨噬细胞复极化中的作用。

背景及目的

巨噬细胞白介素(IL)-10信号在预防IBD发生中起着关键作用。先前已经发现抗肿瘤坏死因子(TNF)单克隆抗体可以通过Fcγ受体(FcγR)信号起作用,并促进促炎性肠巨噬细胞重新极化为CD206 +调节表型。但是尚未检测IL-10在抗TNF诱导的巨噬细胞复极化中的作用。


方法

研究人员使用人类外周血单核细胞和小鼠骨髓衍生的巨噬细胞来研究IL-10的产生和CD206 +调节性巨噬细胞的分化。为了确定抗TNF的功效是否取决于体内的IL-10信号传导以及在哪种细胞类型中,研究人员将CD4 + CD45Rb 高 T细胞转移模型与几种遗传小鼠模型结合使用。


结果

抗TNF疗法以FcγR依赖性方式增加巨噬细胞IL-10的产生,这导致巨噬细胞在体外分化为更具调节性的CD206 +表型。在IBD 的CD4 + CD45Rb 高 T细胞转移模型中,IL-10信号的药理学阻断作用阻止了这些CD206 +调节性巨噬细胞的诱导,并降低了抗TNF治疗的疗效。使用细胞类型特异性IL-10受体突变小鼠,研究人员发现巨噬细胞中的IL-10信号传导而非T细胞中的信号传导对于诱导CD206 +调节性巨噬细胞和抗TNF的治疗反应至关重要。


结论

抗TNF解决肠道炎症的疗效主要取决于巨噬细胞中的IL-10信号传导作用。


原始出处:

Pim J Koelink. Et al. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. GUT. 2019.


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1670785, encodeId=b79416e078579, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Mon Aug 03 17:09:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070149, encodeId=8e3c20e0149f7, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Oct 07 11:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263538, encodeId=24e9126353888, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401744, encodeId=a3e91401e4435, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508249, encodeId=9a0d150824902, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587647, encodeId=5ac5158e647da, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8cd17536453, createdName=xiaoyeshuang, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2020-08-03 mfx808

    #抗TNF#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1670785, encodeId=b79416e078579, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Mon Aug 03 17:09:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070149, encodeId=8e3c20e0149f7, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Oct 07 11:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263538, encodeId=24e9126353888, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401744, encodeId=a3e91401e4435, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508249, encodeId=9a0d150824902, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587647, encodeId=5ac5158e647da, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8cd17536453, createdName=xiaoyeshuang, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-07 grace5700
  3. [GetPortalCommentsPageByObjectIdResponse(id=1670785, encodeId=b79416e078579, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Mon Aug 03 17:09:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070149, encodeId=8e3c20e0149f7, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Oct 07 11:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263538, encodeId=24e9126353888, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401744, encodeId=a3e91401e4435, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508249, encodeId=9a0d150824902, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587647, encodeId=5ac5158e647da, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8cd17536453, createdName=xiaoyeshuang, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-07 bnurmamat

    #IBD#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1670785, encodeId=b79416e078579, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Mon Aug 03 17:09:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070149, encodeId=8e3c20e0149f7, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Oct 07 11:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263538, encodeId=24e9126353888, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401744, encodeId=a3e91401e4435, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508249, encodeId=9a0d150824902, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587647, encodeId=5ac5158e647da, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8cd17536453, createdName=xiaoyeshuang, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-07 snowpeakxu

    #TNF#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1670785, encodeId=b79416e078579, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Mon Aug 03 17:09:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070149, encodeId=8e3c20e0149f7, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Oct 07 11:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263538, encodeId=24e9126353888, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401744, encodeId=a3e91401e4435, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508249, encodeId=9a0d150824902, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587647, encodeId=5ac5158e647da, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8cd17536453, createdName=xiaoyeshuang, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-07 jjjiang0202

    #IL-1#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1670785, encodeId=b79416e078579, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Mon Aug 03 17:09:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070149, encodeId=8e3c20e0149f7, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Oct 07 11:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263538, encodeId=24e9126353888, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401744, encodeId=a3e91401e4435, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508249, encodeId=9a0d150824902, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587647, encodeId=5ac5158e647da, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8cd17536453, createdName=xiaoyeshuang, createdTime=Mon Oct 07 02:09:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-07 xiaoyeshuang

    #IL-10#

    0

相关资讯

JCC:新型遗传风险变异可以预测炎症性肠病患者的抗TNF药物反应效果

临床工作中一项重要的任务是鉴定哪种IBD患有对抗肿瘤坏死因子[TNF]治疗难以起到应答效果,以避免潜在的不良反应并采用不同的治疗策略。本项研究的目的是确定和验证临床和遗传因素,以预测IBD患者的抗TNF反应。

Gut: 抗TNF治疗的引入尚未导致炎症性肠病的住院治疗和肠切除率的下降

为了更好地了解生物制剂治疗对克罗恩病(CD)和溃疡性结肠炎(UC)患者的实际影响,本项研究评估了英夫利昔单抗上市后对住院率和手术率以及公共支付药物成本的影响。

Clin Gastroenterology H:英夫利昔单抗暴露-反应关系与溃疡性结肠炎患者的内镜下愈合相关

虽然目前溃疡性结肠炎(UC)患者使用英夫利昔单抗治疗后的暴露阈值与内镜下愈合并不存在明显关系,但研究人员仍希望能找到相关的实验室指标来预测UC患者内镜下粘膜愈合情况。本项研究的目的是确定UC患者在诱导和维持治疗期间与内镜检查结果相关的英夫利昔单抗浓度阈值。

Dig Dis Sci: 术后早期抗TNF治疗不会增加克罗恩病手术后的并发症

术后抗TNF治疗对克罗恩病手术后感染并发症的影响仍存在争议。术后2-4周使用抗TNF治疗似乎是安全的,但2周内使用安全性尚不清楚。因此,本项研究旨在评估克罗恩病患者腹部手术后2周内开始抗TNF治疗的效果。

JCC: 低剂量甲氨蝶呤与抗TNF联合治疗炎症性肠病与使用大剂量甲氨蝶呤具有相似的疗效

甲氨蝶呤[MTX]是一种众所周知的免疫调节剂,可以用于治疗炎症性肠病[IBD],并且通常与生物制剂联合使用。但目前尚未确定用于联合治疗的理想MTX剂量。本研究旨在研究不同剂量的MTX在IBD中与抗TNF药物一起使用时对疗效和安全性结果的影响。

JCC: 早期抗-TNF治疗与克罗恩病的长期获益相关

在克罗恩病[CD]中,治疗升级的最佳时机仍然是一个具有挑战性的问题,对于抗TNF抗体的早期和晚期给药后其长期预后知之甚少。因此,本项研究对此进行了相关研究。